Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 14, 2014 - Issue 2
Submit an article Journal homepage
537
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients

Joaquín Borrás-BlascoSpecialist in Hospital Pharmacy,Hospital de Sagunto, Pharmacy Service, Avda Ramon y Cajal s/n, Sagunto, E-46520, [email protected]
, PharmD PhD,
Antonio Gracia-PérezSpecialist in Rheumatology,Hospital de Sagunto, Rehabilitation Section, Sagunto, Spain
, MD,
J Dolores Rosique-RoblesSpecialist in Hospital Pharmacy,Hospital de Sagunto, Pharmacy Service, Avda Ramon y Cajal s/n, Sagunto, E-46520, [email protected]
, PharmD PhD,
MD Elvira CasteráSpecialist in Hospital Pharmacy,Hospital de Sagunto, Pharmacy Service, Avda Ramon y Cajal s/n, Sagunto, E-46520, [email protected]
, PharmD &
F Javier AbadSpecialist in Hospital Pharmacy,Hospital de Sagunto, Pharmacy Service, Avda Ramon y Cajal s/n, Sagunto, E-46520, [email protected]
, PharmD PhD
Pages 145-150 | Published online: 21 Dec 2013

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Joaquín Borrás-Blasco & Andres Navarro Ruiz. (2015) Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 71-79.
Read now
Joaquín Borrás-Blasco, M Dolores-Elvira Casterá, Xavier Cortes, J Dolores Rosique-Robles & F Javier Abad. (2014) Economical impact associated with a biological therapy prioritization protocol in patients with rheumatoid arthritis in the Hospital of Sagunto. Expert Opinion on Biological Therapy 14:11, pages 1561-1567.
Read now
Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla, Ottavia Magnani & Francesco Puppo. (2014) Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opinion on Drug Safety 13:5, pages 649-661.
Read now

Articles from other publishers (13)

Yoshiya Tanaka, Josef S. Smolen, Heather Jones, Annette Szumski, Lisa Marshall & Paul Emery. (2019) The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Research & Therapy 21:1.
Crossref
Lluís Puig, Lourdes Rodríguez Fernández-Freire, Ramón Burgos-Pol, Ismael Gomez, Carmen Peral, Susana Gomez & Francisco José Rebollo Laserna. (2019) Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review. Dermatology and Therapy 9:3, pages 479-496.
Crossref
Ruishan Yang, Hongda Liu & Mengpo Fan. (2019) A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis patients. Medicine 98:11, pages e14620.
Crossref
Jordi Gratacós, Petra Díaz del Campo Fontecha, Cristina Fernández-Carballido, Xavier Juanola Roura, Luis Francisco Linares Ferrando, Eugenio de Miguel Mendieta, Santiago Muñoz Fernández, Jose Luis Rosales-Alexander, Pedro Zarco Montejo, Mercedes Guerra Rodríguez & Victoria Navarro Compán. (2018) Recommendations by the Spanish Society of Rheumatology on the Use of Biological Therapies in Axial Spondyloarthritis. Reumatología Clínica (English Edition) 14:6, pages 320-333.
Crossref
Jordi Gratacós, Petra Díaz del Campo Fontecha, Cristina Fernández-Carballido, Xavier Juanola Roura, Luis Francisco Linares Ferrando, Eugenio de Miguel Mendieta, Santiago Muñoz Fernández, Jose Luis Rosales-Alexander, Pedro Zarco Montejo, Mercedes Guerra Rodríguez & Victoria Navarro Compán. (2018) Recomendaciones de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en espondiloartritis axial. Reumatología Clínica 14:6, pages 320-333.
Crossref
Sophie Henaux, Adeline Ruyssen-Witrand, Alain Cantagrel, Thomas Barnetche, Bruno Fautrel, Nathalie Filippi, Cédric Lukas, Bernd Raffeiner, Maurizio Rossini, Yannick Degboé & Arnaud Constantin. (2018) Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Annals of the Rheumatic Diseases 77:4, pages 515-522.
Crossref
Renato de Stefano, Elena Frati, Davide de Quattro & Ludovico de Stefano. (2018) Low Doses of Etanercept Can Be Effective to Maintain Remission in Psoriatic Arthritis Patients. JCR: Journal of Clinical Rheumatology 24:3, pages 127-131.
Crossref
Chak Sing Lau, Allan Gibofsky, Nemanja Damjanov, Sadiq Lula, Lisa Marshall, Heather Jones & Paul Emery. (2017) Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. Rheumatology International 37:11, pages 1789-1798.
Crossref
Victoria Navarro-Compán, Chamaida Plasencia-Rodríguez, Eugenio de Miguel, Alejandro Balsa, Emilio Martín-Mola, Daniel Seoane-Mato & Juan D. Cañete. (2016) Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology 55:7, pages 1188-1194.
Crossref
Larissa Valor, Silvia Díaz-Cerezo, Ana López-Lacey, Ana M. Martínez-Arroyo, Miguel A. Casado & Luis Carreño. (2015) El valor de las terapias biológicas en el tratamiento de las enfermedades reumáticas crónicas. Una revisión sistemática de su evidencia farmacoeconómica en España. PharmacoEconomics Spanish Research Articles 13:2, pages 69-89.
Crossref
. (2015) Etanercept. Reactions Weekly 1564:1, pages 82-82.
Crossref
Denis Poddubnyy & Lianne S. Gensler. (2014) Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Practice & Research Clinical Rheumatology 28:5, pages 807-818.
Crossref
G. Tchernev, C. Guarneri, V. Bevelacqua & U. Wollina. (2014) Carcinoma Cuniculatum in Course of Etanercept: Blocking Autoimmunity but Propagation of Carcinogenesis?. International Journal of Immunopathology and Pharmacology 27:2, pages 261-266.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.